首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Fluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?
【2h】

Fluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?

机译:氟化分子和纳米技术:对抗阿尔茨海默氏病的未来复仇者?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) is a serious health concern, affecting millions of people globally, which leads to cognitive impairment, dementia, and inevitable death. There is still no medically accepted treatment for AD. Developing therapeutic treatments for AD is an overwhelming challenge in the medicinal field, as the exact mechanics underlying its devastating symptoms is still not completely understood. Rather than the unknown mechanism of the disease, one of the limiting factors in developing new drugs for AD is the blood–brain barrier (BBB). A combination of nanotechnology with fluorinated molecules is proposed as a promising therapeutic treatment to meet the desired pharmacokinetic/physiochemical properties for crossing the BBB passage. This paper reviews the research conducted on fluorine-containing compounds and fluorinated nanoparticles (NPs) that have been designed and tested for the inhibition of amyloid-beta (Aβ) peptide aggregation. Additionally, this study summarizes fluorinated molecules and NPs as promising agents and further future work is encouraged to be effective for the treatment of AD.
机译:阿尔茨海默氏病(AD)是一项严重的健康问题,影响了全球数百万人,导致认知障碍,痴呆症和不可避免的死亡。尚无医学上接受的AD治疗。在AD领域,开发AD的治疗方法是一项艰巨的挑战,因为其破坏性症状背后的确切机理仍未完全了解。血脑屏障(BBB)不是局限性的疾病机制,而是开发AD新药的限制因素之一。提出将纳米技术与氟化分子结合作为有希望的治疗方法,以满足穿越BBB通道所需的药代动力学/理化性质。本文回顾了对含氟化合物和氟化纳米颗粒(NPs)进行的研究,这些化合物已设计并经过测试可抑制β-淀粉样蛋白(Aβ)肽的聚集。此外,本研究总结了氟化分子和NPs作为有前途的药物,并鼓励进一步的工作对AD的治疗有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号